Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients: relevance for epitope specific vaccination protocols

Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy
M A PlayerF Marincola

Abstract

Cytotoxic T lymphocytes (CTL) associated in vivo with tumor regression recognize the product of nonmutated genes expressed by most melanoma cells as peptides bound to human leukocyte antigen (HLA) molecules. Multiple HLA-A*0201 restricted peptides derived from melanoma associated antigens (MAA) have been described, and peptide-based vaccination protocols against melanoma are being developed worldwide for the treatment of HLA-A2 melanoma patients based on the assumption that most serologically typed HLA-A2+ individuals will be suitable for such vaccinations. Serologic typing of HLA-A2, however, encompasses a family of at least 17 related alleles recognized by molecular typing techniques and differing at one or more functional residues of the HLA class I molecule. We have recently shown that naturally occurring single-residue variants of HLA-A*0201 are responsible for significant differences in CTL response to MAA-peptide stimulation. Existing data for HLA-A*02 subtype frequencies among whites (who are most affected by melanoma) derive from analyses of Northern European and North American populations that are of similar heritage and predict an exceedingly rare (< 5%) frequency of non-HLA-A*0201 alleles. Melanoma however, affects ...Continue Reading

Citations

Jul 21, 2004·Clinics in Dermatology·Ian KomenakaHoward L Kaufman
Nov 20, 2003·Journal of Translational Medicine·Ping Jin, Ena Wang
Dec 1, 2001·Expert Opinion on Biological Therapy·E WangF M Marincola
Jul 4, 2006·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Emmanuelle GodefroyMaha Ayyoub
Nov 26, 2010·Molecular Immunology·Kirsten Roomp, Francisco S Domingues
Feb 27, 1999·International Journal of Cancer. Journal International Du Cancer·J N CormierF M Marincola
Apr 4, 2003·International Journal of Cancer. Journal International Du Cancer·Maria P BettinottiFrancesco M Marincola
Apr 3, 1998·Annals of Surgical Oncology·C J KimF M Marincola
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·M C PanelliF M Marincola
Aug 5, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·M B NielsenF M Marincola
Nov 8, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Paul F RobbinsSteven A Rosenberg
Feb 18, 1998·International Journal of Cancer. Journal International Du Cancer·J N CormierF M Marincola
Oct 13, 2006·The Journal of General Virology·Jing WeiYu-Zhang Wu
Dec 12, 2018·Journal of Immunological Methods·Soi Cheng LawRaymond J Steptoe
Apr 4, 2021·International Journal of Molecular Sciences·Fanny PojeroAnna Aiello
Aug 23, 2005·Journal of Neuroimmunology·Elisabetta PratRoland Martin
Feb 14, 2006·The Journal of Investigative Dermatology·Ena WangFrancesco M Marincola

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.